Nordson Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended October 31, 2023. Nordson designs and sells precision dispensing, medical, fluid-management, testing and inspection technologies. It reported 66.2% of sales outside the United States and completed the ARAG agricultural spraying solutions acquisition on August 24, 2023. Unless noted, financial amounts below are USD millions; per-share amounts are dollars.
Financial performance and position
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Sales | $2,628.6 | $2,590.3 | Up 1.5%; acquisitions added 3.8%, organic sales declined 1.4%, and currency reduced sales 0.9%. |
| Gross margin | 54.2% | 55.1% | Down 0.9 percentage points, primarily from acquisition inventory step-up amortization and unfavorable currency effects. |
| Operating profit / margin | $672.8 / 25.6% | $702.4 / 27.1% | Profit declined 4.2%; margin fell 1.5 points, reflecting acquisition-related costs and inventory step-up amortization. |
| Net income | $487.5 | $513.1 | Down 5.0%. |
| Diluted EPS | $8.46 | $8.81 | Down 4.1%. |
| Operating cash flow | $641.3 | $513.1 | Up $128.2; working-capital cash use was substantially lower. |
| Capital expenditures | $34.6 | $51.4 | Operating cash flow less capital expenditures was approximately $606.7. |
| Cash and cash equivalents | $115.7 | $163.5 | Down $47.8; about 81% was held by foreign subsidiaries. |
| Total debt | $1,749.3 | $738.8 | Increased about $999.2, principally to fund acquisitions. |
| Dividends declared per share | $2.63 | $2.18 | Increased; cash dividends paid were $150.4 million. |
Interest expense rose to $59.5 million from $22.4 million, due mainly to higher average debt and interest rates. The effective tax rate was 20.8%, compared with 21.0%.
Segments and material changes
- Industrial Precision Solutions: Sales of $1,391.0 million, up 4.0%; operating margin improved to 33.1% from 32.5%. ARAG contributed to acquisition growth.
- Medical and Fluid Solutions: Sales of $660.3 million, down 4.3%; operating margin declined to 28.7% from 31.5%, amid lower demand in fluid product lines, mix changes and factory inefficiencies.
- Advanced Technology Solutions: Sales of $577.3 million, up 2.6%, including acquisition growth despite a 9.2% organic sales decline. Operating margin fell to 17.6% from 23.7%, partly due to $10.3 million of CyberOptics-related fees, severance and non-cash inventory charges, and lower-volume inefficiencies.
ARAG’s all-cash purchase price was approximately €957 million, net of repayment of acquired debt. The acquisition was financed with borrowings; the company issued $350 million of 5.60% notes due 2028 and $500 million of 5.80% notes due 2033, using proceeds to repay its 364-day acquisition loan. ARAG added $694.9 million of goodwill and $353.5 million of identifiable intangible assets; its purchase-price allocation remained preliminary, principally pending income-tax assessment. ARAG and CyberOptics together represented 4% of FY2023 revenue and 30% of year-end assets; their combined net income did not materially affect results.
Cash used in investing activities was $1,436.9 million, including $1,422.8 million for acquisitions. Financing activities provided $750.5 million, including substantial debt proceeds. The 2022 comparison included a $41.2 million non-cash pension settlement charge, a notable unusual item affecting year-over-year earnings comparisons.
Outlook, risks and contingencies
The filing provides no specific numeric revenue or earnings guidance. Management said operating cash generation, available borrowing capacity and capital-market access were expected to be adequate for liquidity needs over the next 12 months and the foreseeable future. The company had a $1.15 billion unsecured credit facility, including a $300 million term loan and an $850 million revolving facility; balances outstanding at year-end were $300 million and $248 million, respectively. Debt covenants were in compliance at October 31, 2023. Of total debt, $553.0 million was floating-rate; management estimated a 1 percentage-point rate increase would add approximately $5.5 million of annual interest expense.
- Key exposures include global economic and end-market weakness, especially cyclical electronics and industrial demand; foreign-exchange movements; inflation, raw-material availability and supply interruptions; tariffs and geopolitical conflicts in Europe and the Middle East.
- Acquisition integration, realizing expected benefits, increased debt and goodwill/intangible-asset impairment are material execution and financial risks.
- Cybersecurity, data privacy, environmental regulation, tax changes, pension assumptions, and retention of key personnel are also identified risks.
- Nordson reported pending or potential ordinary-course litigation but did not expect losses beyond accruals to materially affect its financial condition or results. Its New Richmond, Wisconsin landfill remediation accrual was $0.231 million; the company noted estimates could change, but did not expect a material effect.
- No goodwill impairment was recorded in 2023. The annual impairment test and ARAG customer-relationship valuation involved significant assumptions; the auditor identified both as critical audit matters.
Investor verification points
- Track organic demand and margins by segment, especially continued weakness in Medical and Fluid Solutions and Advanced Technology Solutions.
- Assess ARAG and CyberOptics integration, contribution to growth and returns, and completion of ARAG’s preliminary purchase-price allocation.
- Review debt repayment, refinancing needs, interest-rate exposure and remaining revolving-credit availability against acquisition-driven leverage.
- Monitor cash conversion, working capital, acquisition spending and whether cash generation supports dividends and other capital allocation.
- Note that management’s and the auditor’s internal-control evaluations excluded ARAG and CyberOptics, which together were 30% of year-end assets; both issued unqualified opinions on the audited financial statements and on controls within the evaluated scope.